{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:28:23Z","timestamp":1784572103474,"version":"3.55.0"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"11","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005180","name":"Thermo Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2021-1340_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>All guidelines recommend LC-MS\/MS as the analytical method of choice for the quantification of immunosuppressants in whole blood. Until now, the lack of harmonization of methods and the complexity of the analytical technique have prevented its widespread use in clinical laboratories. This can be seen in international proficiency schemes, where more than half of the participants used immunoassays. With the Cascadion SM Clinical analyzer (Thermo Fisher Scientific, Oy, Vantaa, FI) a fully automated LC-MS\/MS system has been introduced, which enables the use of LC-MS\/MS without being an expert in mass spectrometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-1340_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To verify the interlaboratory comparison of the immunosuppressant assay on this type of instrument, three centers across Europe compared 1097 routine whole blood samples, each site sharing its own samples with the other two. In other experiments, the effects of freezing and thawing of whole blood samples was studied, and the use of secondary cups instead of primary tubes was assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-1340_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the Bland\u2013Altman plot, the comparison of the results of tacrolimus in fresh and frozen samples had an average bias of only 0.36%. The respective data for the comparison between the primary and secondary tubes had an average bias of 1.14%. The correlation coefficients for patient samples with cyclosporine A (n=411), everolimus (n=139), sirolimus (n=114) and tacrolimus (n=433) were 0.993, 0.993, 0.993 and 0.990, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2021-1340_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The outcome of this study demonstrates a new level of result harmonization for LC-MS\/MS based immunosuppressant analysis with a commercially available fully automated platform for routine clinical application.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2021-1340","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T20:47:36Z","timestamp":1661978856000},"page":"1753-1762","source":"Crossref","is-referenced-by-count":8,"title":["Interlaboratory comparison study of immunosuppressant analysis using a fully automated LC-MS\/MS system"],"prefix":"10.1515","volume":"60","author":[{"given":"No\u00ebl","family":"Zahr","sequence":"first","affiliation":[{"name":"Pharmacokinetics and Therapeutic Drug Monitoring Unit, Department of Pharmacology and Clinical Investigation Center (CIC-1901) , AP-HP, Sorbonne Universit\u00e9 , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Duce","sequence":"additional","affiliation":[{"name":"Department of Pathology , University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Duffy","sequence":"additional","affiliation":[{"name":"Department of Pathology , University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Webster","sequence":"additional","affiliation":[{"name":"Department of Pathology , University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina M.","family":"Rentsch","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, University Hospital Basel, University Basel , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"2023033113340201760_j_cclm-2021-1340_ref_001","doi-asserted-by":"crossref","unstructured":"Brunet, M, van Gelder, T, Asberg, A, Haufroid, V, Hesselink, DA, Langman, L, et al.. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 2019;41:261\u2013307. https:\/\/doi.org\/10.1097\/ftd.0000000000000640.","DOI":"10.1097\/FTD.0000000000000640"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_002","doi-asserted-by":"crossref","unstructured":"Shipkova, M, Hesselink, DA, Holt, DW, Billaud, EM, van Gelder, T, Kunicki, PK, et al.. Therapeutic drug monitoring of everolimus: a consensus report. Ther Drug Monit 2016;38:143\u201369. https:\/\/doi.org\/10.1097\/ftd.0000000000000260.","DOI":"10.1097\/FTD.0000000000000260"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_003","doi-asserted-by":"crossref","unstructured":"Yatscoff, RW, Boeckx, R, Holt, DW, Kahan, BD, LeGatt, DF, Sehgal, S, et al.. Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit 1995;17:676\u201380. https:\/\/doi.org\/10.1097\/00007691-199512000-00022.","DOI":"10.1097\/00007691-199512000-00022"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_004","doi-asserted-by":"crossref","unstructured":"Oellerich, M, Armstrong, VW, Kahan, B, Shaw, L, Holt, DW, Yatscoff, R, et al.. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995;17:642\u201354. https:\/\/doi.org\/10.1097\/00007691-199512000-00017.","DOI":"10.1097\/00007691-199512000-00017"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_005","doi-asserted-by":"crossref","unstructured":"Seger, C, Shipkova, M, Christians, U, Billaud, EM, Wang, P, Holt, DW, et al.. Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. Ther Drug Monit 2016;38:170\u201389. https:\/\/doi.org\/10.1097\/ftd.0000000000000269.","DOI":"10.1097\/FTD.0000000000000269"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_006","doi-asserted-by":"crossref","unstructured":"Christians, U, Vinks, AA, Langman, LJ, Clarke, W, Wallemacq, P, van Gelder, T, et al.. Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs. Ther Drug Monit 2015;37:718\u201324. https:\/\/doi.org\/10.1097\/ftd.0000000000000205.","DOI":"10.1097\/FTD.0000000000000205"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_007","doi-asserted-by":"crossref","unstructured":"Vogeser, M, Zhang, YV. Understanding the strategic landscape surrounding the implementation of mass spectrometry in the clinical laboratory: a SWOT analysis. Clin Mass Spectrom 2018;9:1\u20136. https:\/\/doi.org\/10.1016\/j.clinms.2018.06.001.","DOI":"10.1016\/j.clinms.2018.06.001"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_008","doi-asserted-by":"crossref","unstructured":"Dasgupta, A. Impact of interferences including metabolite cross reactivity on therapeutic drug monitoring results. Ther Drug Monit 2012;34:496\u2013506. https:\/\/doi.org\/10.1097\/ftd.0b013e318261c2c9.","DOI":"10.1097\/FTD.0b013e318261c2c9"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_009","doi-asserted-by":"crossref","unstructured":"Ward, G, Simpson, A, Boscato, L, Hickman, PE. The investigation of interferences in immunoassay. Clin Biochem 2017;50:1306\u201311. https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.08.015.","DOI":"10.1016\/j.clinbiochem.2017.08.015"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_010","doi-asserted-by":"crossref","unstructured":"McShane, AJ, Bunch, DR, Wang, S. Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry. Clin Chim Acta 2016;454:1\u20135. https:\/\/doi.org\/10.1016\/j.cca.2015.12.027.","DOI":"10.1016\/j.cca.2015.12.027"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_011","doi-asserted-by":"crossref","unstructured":"Taibon, J, van Rooij, M, Schmid, R, Singh, N, Albrecht, E, Anne Wright, J, et al.. An isotope dilution LC-MS\/MS based candidate reference method for the quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human whole blood. Clin Biochem 2020;82:73\u201384. https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.11.006.","DOI":"10.1016\/j.clinbiochem.2019.11.006"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_012","doi-asserted-by":"crossref","unstructured":"Annesley, TM, McKeown, DA, Holt, DW, Mussell, C, Champarnaud, E, Harter, L, et al.. Standardization of LC-MS for therapeutic drug monitoring of tacrolimus. Clin Chem 2013;59:1630\u20137. https:\/\/doi.org\/10.1373\/clinchem.2013.209114.","DOI":"10.1373\/clinchem.2013.209114"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_013","doi-asserted-by":"crossref","unstructured":"Marinova, M, Artusi, C, Brugnolo, L, Antonelli, G, Zaninotto, M, Plebani, M. Immunosuppressant therapeutic drug monitoring by LC-MS\/MS: workflow optimization through automated processing of whole blood samples. Clin Biochem 2013;46:1723\u20137. https:\/\/doi.org\/10.1016\/j.clinbiochem.2013.08.013.","DOI":"10.1016\/j.clinbiochem.2013.08.013"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_014","doi-asserted-by":"crossref","unstructured":"Zhang, YV, Rockwood, A. Impact of automation on mass spectrometry. Clin Chim Acta 2015;450:298\u2013303. https:\/\/doi.org\/10.1016\/j.cca.2015.08.027.","DOI":"10.1016\/j.cca.2015.08.027"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_015","doi-asserted-by":"crossref","unstructured":"Horber, S, Peter, A, Lehmann, R, Hoene, M. Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS\/MS-based clinical analyzer suggests a new era in laboratory medicine. Clin Chem Lab Med 2021;59:913\u201320. https:\/\/doi.org\/10.1515\/cclm-2020-0848.","DOI":"10.1515\/cclm-2020-0848"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_016","doi-asserted-by":"crossref","unstructured":"Kaplan, I, Yuksel, H, Evliyaoglu, O, Basarali, MK, Toprak, G, Colpan, L, et al.. Effects of storage temperature and time on stability of serum tacrolimus and cyclosporine A levels in whole blood by LC-MS\/MS. Int J Anal Chem 2015;2015:956389. https:\/\/doi.org\/10.1155\/2015\/956389.","DOI":"10.1155\/2015\/956389"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_017","doi-asserted-by":"crossref","unstructured":"Peters, DH, Fitton, A, Plosker, GL, Faulds, D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746\u201394. https:\/\/doi.org\/10.2165\/00003495-199346040-00009.","DOI":"10.2165\/00003495-199346040-00009"},{"key":"2023033113340201760_j_cclm-2021-1340_ref_018","unstructured":"Yatscoff, RW. Pharmacokinetics of rapamycin. Transplant Proc 1996;28:970\u20133."},{"key":"2023033113340201760_j_cclm-2021-1340_ref_019","doi-asserted-by":"crossref","unstructured":"Vogeser, M, Kirchhoff, F. Progress in automation of LC-MS in laboratory medicine. Clin Biochem 2011;44:4\u201313. https:\/\/doi.org\/10.1016\/j.clinbiochem.2010.06.005.","DOI":"10.1016\/j.clinbiochem.2010.06.005"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-1340\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-1340\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T18:32:15Z","timestamp":1680287535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2021-1340\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,8,29]]},"published-print":{"date-parts":[[2022,10,26]]}},"alternative-id":["10.1515\/cclm-2021-1340"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2021-1340","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}